Navigation Links
A New Marker to Spot Aggressive Breast Cancers?
Date:8/4/2010

By Kathleen Doheny
HealthDay Reporter

WEDNESDAY, Aug. 4 (HealthDay News) -- Low cellular levels of a protein known as ferroportin are tied to recurrent, aggressive breast cancers, new research suggests.

Testing levels of this protein, which eliminates iron from cells, may someday help doctors better predict which breast cancers will return and which need more intensive treatment, the researchers say.

"We had a hint that iron might be important in cancer in general, and particularly in breast cancer, but it hadn't been deeply studied," said Dr. Frank Torti, lead author of the new study and director of the Comprehensive Cancer Center at Wake Forest University Baptist Medical Center, Winston-Salem, NC.

Torti and his team report their findings online Aug. 4 in the journal Science Translational Medicine.

They first looked at isolated human breast cancer cells, finding a low level of the protein in breast cancer cells compared to normal breast cells.

Then, in a series of experiments, the team artificially boosted the protein to near normal levels in an aggressive breast cancer cell line. They found that the cancer cells grew much slower in the presence of added ferroportin.

The researchers also examined levels of the protein in human breast cancer tissue and found the lowest ferroportin levels occurring in the most aggressive cancers.

When they looked at gene activity profiles from more than 800 women included in four large study databases from around the world, the researchers found that decreased ferroportin gene expression is linked with a reduction in breast cancer survival. But high expression is linked with a favorable outcome -- namely, a 10-year survival of more than 90 percent.

The research is in early stages, but may eventually help doctors make a more accurate prognosis for breast cancer, using levels of ferroportin along with other markers such as tumor size and lymph node status, Torti said.

''One day, this discovery may lead to the development of a tissue test which can help predict recurrences based on ferroportin levels," he said. But for now, "we want to look at a larger group of women to confirm the results," Torti said.

"The initial studies they have done suggest this may be another way of predicting the behavior of breast cancer in additon to other available tests," added Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society. "However, as he [Torti] says, there is more research to be done." Whether the finding will prove to be clinically useful, he said, remains to be seen.

Another expert agreed. "If the findings bear out, testing for ferroportin might someday spare women from unnecessary treatments," said Susan Kane, professor of tumor cell biology at the City of Hope cancer center in Duarte, Calif.

"There is some thought that we overtreat, because it is difficult to determine [who needs which treatment to prevent recurrences]," Kane noted.

More information

To learn more about breast cancer, visit the American Cancer Society.

SOURCES: Frank M. Torti, M.D., M.P.H., director, Comprehensive Cancer Center, Wake Forest University Baptist Medical Center, Winston-Salem, N.C.; Len Lichtenfeld, M.D., deputy chief medical officer, American Cancer Society, Atlanta,; Susan Kane, Ph.D., professor, division of tumor cell biology, City of Hope, Duarte, Calif.; Science Translational Medicine, Aug. 4, 2010, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Marker of Ewing sarcoma: Potential new drug target?
2. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
3. Personalizing cancer: Creating biomarkers from tumor DNA
4. Damaged protein identified as early diagnostic biomarker for Alzheimers disease in healthy adults
5. Reliable biomarkers needed for early detection of liver cancer
6. More Reliable Biomarkers Needed for Early Detection of Liver Cancer
7. Voyant Health, Ltd. Announces the Launch of KingMark™, a Pioneering Calibration Marker that Calculates the Radiological Magnification of the Hip
8. UAB researchers find 4 biomarkers important in colerectal cancer treatment prognosis
9. BATTLE links potential biomarkers to drugs for lung cancer
10. UAB researchers find 4 biomarkers important in colorectal cancer treatment prognosis
11. Increased EGFR levels may be an early marker of breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A New Marker to Spot Aggressive Breast Cancers?
(Date:2/13/2016)... ... 13, 2016 , ... Valentine’s Day is nearly upon us, and most singles ... great outfit, flawless hair, and a sparkling personality are all well and good, but ... night at home with Rover. (Actually, man’s best friend might not even want to ...
(Date:2/13/2016)... ... February 13, 2016 , ... Many individuals looking to lead a healthy lifestyle ... reasons. IsoPasta by Isolator Fitness has delved into this niche allowing those giving ... high-carb repercussions. IsoPasta has 30 grams of protein and only 7 grams of ...
(Date:2/13/2016)... ... February 13, 2016 , ... The producers of Enterprises TV are ... The increasingly modern world of instantaneous consumption proves very convenient for businesses. With new ... oil and coal, which pollutes our air, water, and soil. It can also threaten ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical Holdings, Inc. presented ... a VeinViewer® Vision vein finder for the nursing school simulation lab. ... and draw blood, combining technology with traditional technique. , “VeinViewer is a wonderful ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... In the ... forward. They’ll groom themselves to perfection, go out of their way to be romantic, ... – just take a look at any online dating profile. , A recent ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... and Company (NYSE: LLY ) today announced that the ... patent would not presently be infringed by Actavis marketing pemetrexed ... Italy and Spain ... --> --> In ... Lilly,s patent would be indirectly infringed by Actavis marketing certain ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis Pharmaceuticals, ... a $47.1 million Series D preferred stock ... Management, Hillhouse Capital Group and venBio Global ... Investments, AJU IB Investment, and Epidarex Capital. The ... to further advance clinical trials in the ...
(Date:2/11/2016)... , Feb. 11, 2016 The primary goal ... future adoption patterns on the usage of liquid biopsy. ... following: - Timeframe of liquid biopsy adoption ... cfDNA and Evs—by organization type - Sample inflow to ... blood, saliva, stool, serum, and so on. - Correlation ...
Breaking Medicine Technology: